MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

Core Insights - MindRank has initiated a pivotal Phase III clinical trial named "MOBILE" for its lead candidate, MDR-001, an orally available GLP-1 receptor agonist aimed at chronic weight management [1][2] - MDR-001 is notable for being one of the first AI-designed molecules to reach Phase III, achieving this milestone in just 4.5 years, showcasing the efficiency of MindRank's AI-driven drug discovery platform [2][7] Phase III MOBILE Trial Design - The MOBILE trial aims to enroll approximately 750 participants with overweight or obesity in China to evaluate the efficacy and safety of MDR-001 over a 52-week period [4] Phase IIb Results Summary - In the Phase IIb study involving 317 participants, MDR-001 demonstrated a mean weight reduction of 10.3% after 24 weeks of treatment [7][8] - The safety profile was favorable, with a treatment-emergent adverse events (TEAE) related discontinuation rate of only 0.8% [7][8] - Significant cardiometabolic improvements were observed, including reductions in uric acid levels, waist circumference, blood pressure, lipid profiles, fasting plasma glucose (FPG), and HbA1c [8] Company Overview - MindRank is a clinical-stage AI drug discovery company focused on developing innovative small molecule drugs targeting metabolic diseases and oncology [6]